News & Events

BioEclipse Therapeutics™ Awarded Almost $8 Million Grant by California Institute for Regenerative Medicine (CIRM) to Fund Ongoing Phase 1 CRX100 Cancer Immunotherapy Clinical Trial

BioEclipse Therapeutics announced today it has been awarded a $7,999,689.00 grant by the California Institute for Regenerative Medicine (CIRM) to support its ongoing clinical study: A Phase 1, open-label, dose-escalation study of CRX100 in patients with advanced solid tumors....

26 April, 2022

BioEclipse Therapeutics Appoints New Board Member and Names Interim CFO

Mahmoud Mahmoudian, Ph.D.,FRSC, Joins BioEclipse Board; Biopharmaceutical Industry Veteran with Proven Track Record in R&D, Venture Investments, and Business Development Stephen Ghiglieri, Managing Director at Danforth Advisors, to Serve as Interim CFO   MOUNTAIN VIEW, Calif., Jan. 26, 2022 /PRNewswire/ --  BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing...

26 January, 2022

72 Top San Francisco Therapeutics Companies and Startups of 2021

Best StartUp - This article showcases our top picks for the best San Francisco based Therapeutics companies. These startups and companies are taking a variety of approaches to innovating the Therapeutics industry, but are all exceptional companies well worth a follow. We tried to pick companies across the size spectrum from cutting...

07 January, 2022

Discover 5 Top Pharma Startups tackling Ovarian Cancer

StartUp Insights - Global Startup Heat Map highlights 5 Top Startups tackling Ovarian Cancer out of 140   The insights of this data-driven analysis are derived from the Big Data & Artificial Intelligence-powered StartUs Insights Discovery Platform, covering 2.093.000+ startups & scaleups globally. The platform gives you an exhaustive overview of emerging technologies &...

04 January, 2022

BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Clinical Trial for CRX100 at HonorHealth Research Institute

First-in-Human Trial to Enroll Up to 24 Patients with Refractory Solid Tumors   MOUNTAIN VIEW, Calif., Jan. 19, 2021 /PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the initiation of patient enrollment at the HonorHealth Research Institute in Scottsdale, Ariz. for a Phase 1 dose-escalation trial to...

19 January, 2021

BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Clinical Trial for CRX100

BioEclipse Therapeutics™ today announced today the initiation of patient enrollment in a Phase 1 dose-escalation trial to treat refractory solid tumors. The trial marks the first-in-human study of CRX100, an intravenously-delivered cancer therapy designed to target and destroy multiple cancer types and address disease recurrence....

21 December, 2020

Designing Immunotherapies that Can Overcome Recurrence and Resistance

BioEclipse Therapeutics CEO Dr. Pam Contag, shares with Dan Levine, host of The Bio Report, about the ability of cancers to return after treatment with immunotherapies, BioEclipse’s efforts to develop a multi-mechanistic immunotherapy to overcome that challenge, and why its approach may have broad application across a range of cancers....

22 October, 2020

Accelerating Your Biopharma Startup’s Path To The Clinic

Best practices and lessons learned during the drive to get a biopharmaceutical startup to the clinic as quickly as possible....

25 September, 2020

The Benefit Of Having A Highly Engaged Editorial Advisory Board

One of Life Science Leader’s newest editorial advisory board (EAB) members is Pamela Reilly Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics....

31 July, 2020

A Small Biopharma’s View Of Working With CROs

Running a clinical-stage oncology biopharma with only five employees means you quickly learn a thing or two about the value of outsourcing services....

01 July, 2020